Condensed Financial Information of Parent Company

12 Months Ended

Dec. 31, 2024

GoodRx Holdings, Inc. has no material assets or standalone operations other than its ownership in its consolidated

subsidiaries. Under the terms of debt agreements entered into by GoodRx, a wholly-owned subsidiary of GoodRx

Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc., GoodRx is restricted from

making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. These

restrictions have resulted in the restricted net assets (as defined in Rule 1-02 of Regulation S-X) of GoodRx and its

subsidiaries to exceed 25% of the consolidated net assets of GoodRx Holdings, Inc. and its subsidiaries.

The condensed financial information is presented on a “parent-only” basis, and GoodRx Holdings, Inc.’s investment in

its subsidiary is stated at cost plus equity in earnings (loss) of subsidiary less distributions received from subsidiary since the

date of acquisition. GoodRx Holdings. Inc.’s share of net income (loss) of its subsidiary is included in net income (loss) using

the equity method of accounting.

During 2024, 2023 and 2022, GoodRx Holdings, Inc. received no dividends from its subsidiary.

The following table presents the parent-only balance sheets of GoodRx Holdings, Inc.:


(in thousands, except par values)	December 31, 2024	December 31, 2023
Assets
Cash	$30	$5
Other assets	—	164
Investment in subsidiary, net of distributions	724,628	761,790
Total assets	$724,658	$761,959
Liabilities and stockholders' equity
Total liabilities	$—	$1
Stockholders' equity
Preferred stock, $0.0001 par value	—	—
Common stock, $0.0001 par value	38	40
Additional paid-in capital	2,165,633	2,219,321
Accumulated deficit	(1,441,013)	(1,457,403)
Total stockholders' equity	724,658	761,958
Total liabilities and stockholders' equity	$724,658	$761,959

The following table presents the parent-only statements of operations of GoodRx Holdings, Inc.:


	Year Ended December 31,
(in thousands)	2024	2023	2022
Equity in earnings (loss) of subsidiary	$16,390	$(8,868)	$(32,828)
Net income (loss)	$16,390	$(8,868)	$(32,828)

The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc.:


	Year Ended December 31,
(in thousands)	2024	2023	2022
Cash flows from operating activities
Net income (loss)	$16,390	$(8,868)	$(32,828)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in (earnings) loss of subsidiary	(16,390)	8,868	32,828
Changes in assets and liabilities:
Other assets	164	(164)	80
Other current liabilities	(1)	1	—
Net cash provided by (used in) operating activities	163	(163)	80
Cash flows from investing activities
Distribution from subsidiary	167,679	162,287	113,117
Net cash provided by investing activities	167,679	162,287	113,117
Cash flows from financing activities
Repurchases of Class A common stock	(158,845)	(103,974)	(101,721)
Proceeds from exercise of stock options	19,046	5,941	9,159
Employee taxes paid related to net share settlement of equity awards	(29,784)	(65,481)	(20,635)
Proceeds from employee stock purchase plan	1,766	1,390	—
Net cash used in financing activities	(167,817)	(162,124)	(113,197)
Net change in cash	25	—	—
Cash
Beginning of period	5	5	5
End of period	$30	$5	$5